Recombinant Human CD4 Protein, Fc Tag (MALS verified) DMF Filed, 200µg

Background
T-cell surface glycoprotein CD4 is also known as T-cell surface antigen T4/Leu-3. CD4 contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CD4 is accessory protein for MHC class-II antigen/T-cell receptor interaction. CD4 induces the aggregation of lipid rafts. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.

Source
Recombinant Human CD4, Fc Tag (MALS verified) (CD4-H5259) is expressed from human 293 cells (HEK293). It contains AA Lys 26 - Pro 396 (Accession # AAH25782).
Predicted N-terminus: Lys 26

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 67.5 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris, Glycine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 12 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Systemic inflammation and cortical neurochemistry in never-medicated first episode-psychosis individuals"
León-Ortiz, Rivera-Chávez, Torres-Ruíz et al
Brain Behav Immun (2023)
(2) "Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study"
Ravussin, Robertson, Wolf et al
Lancet Healthy Longev (2023) 4 (5), e188-e199
(3) "Synergistic cancer immunotherapy utilizing programmed Salmonella typhimurium secreting heterologous flagellin B conjugated to interleukin-15 proteins"
Zhang, Tan, Sultonova et al
Biomaterials (2023) 298, 122135
Showing 1-3 of 183535 papers.